Efficacy of procaterol and montelukast on children with moderate persistent asthma
10.3760/cma.j.issn.1008-6706.2016.14.022
- VernacularTitle:丙卡特罗联合孟鲁斯特治疗儿童中度持续性支气管哮喘疗效观察
- Author:
Shuying YAO
;
Ying XU
- Publication Type:Journal Article
- Keywords:
Bronchial asthma;
Procaterol;
Montelukast
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(14):2162-2165
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of procaterol and montelukast on lung function in children with moderate persistent asthma.Methods 86 children with moderate persistent asthma from January 2014 to December 2014 in our hospital were studied,and according to the random number table method,they were divided into the control group and the observation group,43 cases in each group.The observation group was treated with procaterol combined with montelukast,the control group was treated with procaterol.The cough relief and disappearance time,the improvement of pulmonary function after treatment,the clinical effect and the control of asthma after one month of the two groups were compared.Results After treatment,children cough relief and disappeared time of the observation group was significantly shorter than the control group (t =4.418 5,3.784 4,P =0.000 0,0.000 3).After treatment, the pulmonary function was found to improve the situation of the observation group being good than the control group, PEF,FVC,FEV1 ,FEV1 /FVC predicted values were significantly higher than the control group (all P <0.05).The total effective rate of the observation group (93.00%)was significantly higher than 74.40% of the control group (u =2.223 2,P =0.026 2).After one month of treatment,the basic control rate of the observation group(88.37%) was significantly higher than 67.40% of the control group(u =2.386 6,P =0.017 0).The incidence rate of adverse reactions of the observation group (6.98%)was significantly lower than 51.16% of the control group(P <0.05). Conclusion Procaterol combined with montelukast in the treatment of children with moderate persistent bronchial asthma can improve clinical efficacy,safety,and improve symptom control rate,it is worthy of promotion.
